SYN-Tech Chem & Pharm Co Ltd

SYN-Tech maintains a strong liquidity position, with a current ratio of 5.03 and cash and equivalents of TWD 858.19 million, representing 29% of total assets. The company's debt-to-equity ratio is 0.07, indicating a conservative capital structure with minimal leverage. Free cash flow of TWD 114.10 million and operating cash flow of TWD 559.49 million support operational flexibility and reinvestment capacity. Profitability metrics show a return on equity (ROE) of 10.1% and return on assets (ROA) of 8.84%, both exceeding the typical thresholds for pharmaceutical firms, which often range between 5-10% for ROE and 3-7% for ROA. Gross profit of TWD 450.36 million and operating income of TWD 319.98 million reflect efficient cost management and pricing power in its API markets. The company's revenue is distributed across human medicine APIs, animal medicine APIs, and excipients, with no disclosed segment accounting for more than 50% of total revenue. Geographically, it operates in Taiwan, Asia, Europe, and America, though revenue concentration by region is not specified in the latest financials. Growth trajectory is not explicitly quantified in the latest data, but the company's operating income and net income suggest stable performance. Capital expenditures of TWD -58.31 million indicate a reduction in investment, potentially reflecting a focus on optimizing existing production capacity. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and high cash reserves reduce exposure to interest rate volatility and refinancing risk. No dilution sources were identified in the latest filings, and the probability of near-term dilution remains low. Recent events include no material changes in financial position or operations as disclosed in the latest financial snapshot. The company continues to focus on its core API production and global market expansion.